ReposiTrak, Inc. (TRAK) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with increased revenue, operating income, and net income. The SaaS model shows scalability, and the company's financial health is robust with no debt and strong liquidity. Shareholder returns are positive with share repurchases and dividend increases. The Q&A section reveals cautious optimism regarding partnerships and a focus on operational efficiency. Despite some uncertainty in KPIs for new partnerships, the overall sentiment is positive due to financial strength and growth potential.
Key Financial Performance
Revenue (Q3 Fiscal 2026) $5.9 million, flat year-over-year compared to $5.9 million in the prior year quarter. The March quarter of fiscal 2025 benefited from elevated traceability onboarding activity ahead of the original FDA compliance deadlines, which contributed to approximately 16% revenue growth during that period. The FDA's extension of the FSMA 204 compliance deadline caused a temporary timing shift in onboarding activity, impacting revenue growth.
Operating Expenses (Q3 Fiscal 2026) $3.6 million, decreased 12% year-over-year compared to $4.1 million in the prior year period. The reduction reflects operational discipline and efficiency improvements.
Income from Operations (Q3 Fiscal 2026) $2.3 million, increased 24% year-over-year compared to $1.8 million in the prior year quarter. This increase demonstrates the operating leverage embedded within the SaaS model.
GAAP Net Income (Q3 Fiscal 2026) $2 million, increased 1% year-over-year. The increase was impacted by a 200% rise in tax expense, representing a $300,000 increase, due to the absence of significant net operating loss carryforwards to offset taxable income.
Net Income Attributable to Common Shareholders (Q3 Fiscal 2026) $2 million, increased 4% year-over-year. The increase reflects improved profitability despite higher tax expenses.
Effective Tax Rate (Q3 Fiscal 2026) Approximately 18%, increased significantly from the prior year period due to the absence of net operating loss carryforwards.
Basic Earnings Per Share (Q3 Fiscal 2026) $0.11 per share, reflecting stable profitability.
Diluted Earnings Per Share (Q3 Fiscal 2026) $0.10 per share, reflecting stable profitability.
Year-to-Date Revenue (First 9 Months Fiscal 2026) $17.7 million, increased 5% year-over-year compared to $16.8 million in the prior year period. The increase reflects sustainable recurring revenue growth.
Year-to-Date Operating Expenses (First 9 Months Fiscal 2026) $11.7 million, declined 4% year-over-year. The reduction reflects operational discipline and efficiency improvements.
Year-to-Date Income from Operations (First 9 Months Fiscal 2026) $6 million, increased 28% year-over-year compared to $4.6 million in the prior year period. This increase demonstrates the scalability of the SaaS model.
Year-to-Date GAAP Net Income (First 9 Months Fiscal 2026) $5.5 million, increased 6% year-over-year. The increase reflects improved profitability and operational efficiency.
Year-to-Date Net Income to Common Shareholders (First 9 Months Fiscal 2026) $5.4 million, increased 9% year-over-year. The increase reflects improved profitability and operational efficiency.
Year-to-Date Diluted Earnings Per Share (First 9 Months Fiscal 2026) $0.28 per share, increased 9% year-over-year compared to $0.26 per share in the prior year period. The increase reflects improved profitability.
Cash Position (End of Q3 Fiscal 2026) $26.4 million, with 0 bank debt, reflecting strong liquidity and financial health.
Operating Cash Flow (First 9 Months Fiscal 2026) $6 million, reflecting strong cash generation.
Share Repurchases (Fiscal 2026) 144,000 common shares repurchased for approximately $1.8 million at an average purchase price of $12.50 per share. Since inception of the buyback program, 2.3 million shares have been repurchased for approximately $15 million at an average cost of $6.60 per share.
Preferred Share Redemptions (Fiscal 2026) 175,000 preferred shares redeemed, with approximately 161,000 shares left outstanding.
Dividend (Q3 Fiscal 2026) Quarterly cash dividend of $0.02 per share declared, marking the third consecutive annual 10% increase since the program's initiation in September 2022.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Touchless Traceability: ReposiTrak introduced the Touchless Traceability initiative, an AI-powered self-learning automated solution for FDA-compliant traceability. It eliminates manual scanning, uses electronic data, and ensures efficiency at scale. Two leading grocery entities in the Southern U.S. have achieved full end-to-end traceability using this solution.
Intellectual Property Expansion: Filed two additional patents, one for Touchless Traceability and another for identifying and correcting data integrity issues in supply chains. ReposiTrak now holds nine U.S. patents.
SPAR Group Collaboration: Formed a collaboration with SPAR Group to address in-store execution issues, such as restocking shelves and addressing recalls. This partnership bridges the gap between identifying and resolving retail issues, providing a competitive edge.
Recurring Revenue Model: Transitioned to a SaaS model, increasing recurring revenue from 62% in fiscal 2020 to over 98% in fiscal 2026. Eliminated $2 million of low-margin revenue opportunities to focus on high-value streams.
Cost Reduction and Profitability: Reduced annual operating expenses from $19 million in fiscal 2020 to $16 million in fiscal 2026. Net margins expanded from 8% to over 30% during the same period.
Cash Flow and Debt Management: Net cash compounded at 16% annually since fiscal 2020, increasing from $13.7 million to $28 million by fiscal 2025. Eliminated $6.4 million of bank debt, maintaining strong liquidity.
Platform Scalability and AI Integration: Modernized software architecture with AI initiatives to enhance automation, workflow efficiency, and scalability without significant cost increases.
Capital Allocation: Returned $5 million to shareholders in fiscal 2026 through share repurchases, preferred share redemptions, and dividends. Increased common dividend three times by 10% each since 2022.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Compliance Deadlines: The FDA's extension of the FSMA 204 compliance deadline has caused a temporary timing shift in onboarding activity, impacting revenue growth.
Supplier Data Accuracy: High error rates in supplier data (50%-70%) pose risks to traceability and supply chain operations, potentially leading to incorrect data being passed through the supply chain.
AI-Developed Software Threats: Potential future threats from AI-developed software could challenge the company's competitive positioning, though efforts are being made to mitigate this risk through intellectual property protection.
Economic and Operational Lag in Traceability Revenue: The lag time for traceability revenue and customer implementation is longer compared to other services, which could delay financial benefits.
Labor Shortages in Retail: Retail labor shortages create challenges in executing in-store problem resolutions, such as restocking shelves or addressing recalls.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects sustainable recurring revenue growth driven by its SaaS platform and traceability solutions. The traceability market is expected to grow as FDA compliance deadlines approach, with increasing inquiries and new starts anticipated.
Profitability Expansion: ReposiTrak aims to continue expanding profitability through operational discipline, scalability of its SaaS platform, and cost-effective solutions. The company has modeled an effective tax rate of approximately 20% going forward.
Capital Allocation: The company plans to maintain a balanced approach to capital allocation, including reinvestment in innovation, share repurchases, and dividend increases. It has $6 million remaining under the existing Board authorization for share buybacks.
Traceability Solutions: ReposiTrak is launching its Touchless Traceability solution, which is expected to drive growth in the traceability market. The solution is AI-powered, self-learning, and designed to comply with FDA mandates efficiently and at scale.
Market Trends: The company anticipates growing demand for traceability solutions due to regulatory requirements and increasing complexity in supply chain environments. It expects this trend to accelerate over the next several years.
Strategic Partnerships: ReposiTrak has formed a collaboration with SPAR Group to address in-store execution issues, such as restocking shelves and addressing recalls. This partnership is expected to enhance the company's service offerings and create a competitive advantage.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program Initiation: The company initiated a dividend program in September 2022.
Dividend Increases: The common dividend has been increased three times by 10% each time since the program's initiation.
Recent Dividend Declaration: On March 20, 2026, the Board declared a quarterly cash dividend of $0.02 per share, marking the third consecutive annual 10% increase.
Share Repurchase Program: The company has repurchased approximately 2.3 million shares for $15 million since the program's inception, with an average cost of $6.60 per share.
Fiscal 2026 Share Repurchases: During fiscal 2026, 144,000 common shares were repurchased for $1.8 million at an average price of $12.50 per share.
Remaining Authorization: The company has $6 million remaining under the existing Board authorization for share repurchases.
Preferred Share Redemptions: During fiscal 2026, 175,000 preferred shares were redeemed, leaving approximately 161,000 shares outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on Agentic commerce and its impact on the food retail category?
A:Randall Fields explained that while Agentic commerce is a hot topic, its impact on the food retail category is limited. He highlighted that the grocery business is people-intensive and already highly efficient, with limited opportunities for AI to provide significant benefits. He mentioned that automation efforts, like those by Kroger, have not been very successful. Fields emphasized that the focus should be on fixing issues rather than just identifying them, which is what their organization is working on.
Q:How can investors measure the success of the SPAR Group partnership? What are the KPIs?
A:Randall Fields stated that it is too early to see the KPIs for the SPAR Group partnership. However, he expects financial impacts to be visible in about 6 months. He shared an example of a promising presentation to a major CPG drug company, which showed strong interest in the partnership. Fields indicated that the revenue from such deals should materialize in 6 to 9 months and emphasized the potential scale of these opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific KPIs for the SPAR Group partnership, stating that it is too early to measure success. The response lacked detailed metrics or clear benchmarks for investors to track progress.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA compliance
FDA extension
SPAR
SaaS model
Touchless Traceability
area
buyback program
cash capital
cash flow
compliance deadline
consistency
discipline
environment
expansion
flow generation
framework
intelligence
margin
month
objective
onboarding activity
period Income
platform cash
portfolio patent
program share
property portfolio
reinvestment
scalability platform
shareholder return
shareholder value
strength
tax rate
term shareholder
transition
TRAK Transcript
ReposiTrak, Inc. (TRAK) Q3 2026 Earnings Call Transcript
Positive5-14
The earnings call highlights strong financial performance with increased revenue, operating income, and net income. The SaaS model shows scalability, and the company's financial health is robust with no debt and strong liquidity. Shareholder returns are positive with share repurchases and dividend increases. The Q&A section reveals cautious optimism regarding partnerships and a focus on operational efficiency. Despite some uncertainty in KPIs for new partnerships, the overall sentiment is positive due to financial strength and growth potential.
ReposiTrak, Inc. (TRAK) Q2 2026 Earnings Call Transcript
Unknown2-17
The earnings call reflects a mixed outlook. Revenue and income have grown, but the growth rate is modest. The company is effectively managing expenses and returning capital to shareholders, yet the guidance lacks clarity, especially regarding Traceability revenue and investment spending. The Q&A section highlights potential benefits from AI and food safety awareness but also reveals uncertainties in financial reporting and strategic focus. With no market cap provided, the impact is uncertain, leading to a neutral prediction for the stock price movement.
ReposiTrak, Inc. (TRAK) Q1 2026 Earnings Call Transcript
Positive11-13
The earnings call reveals solid financial performance with revenue and income from operations up, despite higher expenses. The company demonstrates a strong shareholder return plan with dividend increases and share buybacks. Although there are challenges like modernization costs and competitive pressures, the company has a clear strategy for market expansion and automation. The Q&A section did not reveal significant negative sentiment, and the company's strategic initiatives, like expanding traceability, are promising. Overall, the positive financial metrics, shareholder returns, and strategic growth plans suggest a positive stock price movement.
ReposiTrak, Inc. (TRAK) Q4 2025 Earnings Call Transcript
Positive9-29
The earnings call summary indicates strong financial performance with significant year-over-year growth in net income, EPS, and cash from operations, alongside effective cost management. The Q&A section reveals no immediate risks from tariffs and a cautious approach to M&A, which is positive. However, management's vague responses on M&A and the absence of crypto plans slightly temper enthusiasm. Overall, the financial health and growth prospects suggest a positive stock price movement, likely between 2% to 8%.
TRAK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
